JP2003212749A - INHIBITOR OF AGEs FORMATION AND SKIN CARE PREPARATION COMPRISING THE SAME - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an inhibitor of advanced glycation end products (AGEs) formation and a skin care preparation comprising the same as an active ingredient. <P>SOLUTION: This inhibitor of the AGEs formation comprises one or more ingredients of an extract from a plant of the Paeonia L., an extract from a plant of the Scutellaria L., an extract from a plant of the Melissa L., an extract from a plant of the Helianthus L., an extract from a plant of the Aloe L., an extract from a plant of the Polygonatum Adans, an extract from a plant of the Linum L., an extract from a plant of the Rosa L., an extract from a plant of the Tilia L., an extract from a plant of the Heterotropa Morr. et Decne, an extract from a plant of the Houttuynia Thunb., an extract from a plant of the Tussilago L., an extract from a plant of the Sanguisorba L., an extract from a plant of the Mentha L., and an extract from a plant of the Sambucus L. The skin care preparation comprises the one or more kinds of the plant extracts as the inhibitor of the AGEs formation. <P>COPYRIGHT: (C)2003,JPO

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to an agent for suppressing the production of advanced glycation end products (hereinafter abbreviated as AGEs) and a skin external preparation containing the same.

[0002]

2. Description of the Related Art It is unavoidable that anyone loses elasticity due to aging, and becomes dull and rough skin, resulting in rough skin. In the field of cosmetics science, elucidation of such skin aging phenomenon has become a major theme. Many of the research results of our predecessors have shown that the formation of active oxygen causes reactions such as cross-linking and disconnection of the tissue structure such as collagen, and the components that make up the skin undergo a chemical reaction, so that it may be colored or insolubilized. It is said to be the cause of skin aging. As such an aging model, the Maillard reaction, which is a Schiff base formation reaction between sugar and albumin or amino acid, has been considered. The formed AGEs are substances characterized by fluorescence, brown color, cross-linking, and the like, and this phenomenon occurs in various places in the skin and the living body. Proteins with slow metabolism such as collagen and elastin tend to be targeted, and it is particularly remarkable in substances such as elastin having many amino groups in its side chain. These proteins are considered to be the cause of loss of elasticity, firmness, etc., because these proteins are cross-linked and denatured by the generation of AGEs.
In other words, as AGEs are generated and accumulated in the skin, elasticity and firmness are chronically lost, and AG
Since Es is brown, it is considered that there is a mechanism in which the color of the entire skin turns brown or becomes yellow, which leads to chronic darkening. However, since the generated AGEs cannot be easily metabolized, it has been the reality that the idea of decomposing and removing is difficult to be an index for true prevention and improvement of aging.
Therefore, there has been a strong demand for the development of a skin external preparation having a true aging skin protection and improvement effect by using the effect of suppressing the generation of AGEs as an index.

[0003] In addition, Botanus plant extract, Scutellaria plant extract, Saturniidae plant extract, Sunflower plant extract, Aloe plant extract, Amadochorus plant extract, Flax plant extract, Rose genus 1 or 2 of a plant extract, a linden plant extract, a citrus plant extract, a Dodami plant extract, a citrus plant extract, an oleracea plant extract, a mint plant extract, an elderberry plant extract It has not been known at all that the components of one kind or more exhibit an action of suppressing the generation of AGEs. Therefore, Botanus plant extract, Scutellaria genus plant extract, Astragalus genus plant extract, Sunflower plant extract, Aloe genus plant extract, Amadochorus plant extract, flaxseed plant extract excellent in such characteristics , 1 rose plant extract, linden plant extract, algal genus plant extract, dodami plant extract, licorice plant extract, oleander plant extract, mint plant extract, elderberry plant extract 1
There has been no development of an external preparation for skin which contains one or two or more components as an AGEs production inhibitor and has an effect of protecting and improving yellow skin and aging skin.

[0004]

SUMMARY OF THE INVENTION The present invention has been made under such circumstances, and it is an inhibitor of AGEs formation, and the effect of suppressing the formation of AGEs to prevent and improve the effects of yellow erythema and aging skin. An object is to provide a skin external preparation having

[0005]

[Means for Solving the Problems] In order to solve the above-mentioned problems, various investigations were carried out. As a result, an extract of the genus Botanicus, an extract of the genus Spodoptera, an extract of the genus Spodoptera genus, an extract of the sunflower genus, aloe Genus plant extract, flaxseed plant extract, flaxseed plant extract, rose genus plant extract, linden plant extract, algal genus plant extract, doxamid plant extract, citrus plant extract, oleander plant One or more components of the extract, the mint plant extract, and the elderberry plant extract contain AGE.
s production, or an external preparation for skin containing it as an AGEs production inhibitor, exerts an effect of preventing and improving the effects of yellow tinge and aging skin, and also provides safety for skin irritation and skin sensitization. It was found that a problem-free external preparation for skin was obtained, and the present invention was completed.

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described.

The Paeonia L. plant used in the present invention is a Ranunculaceae plant, which is a herb or shrub distributed in the temperate and subarctic regions of Eurasia and western North America. Button (Paeonia
suffruticosa Andr.) and peony ( Paeonia lactif)
lora Pall.) is mentioned as a preferable example. Button (Paeonia suffruticosa Andr.) Is widely cultivated as a flower tree, but is useful not only for ornamental purposes but also for medicinal purposes. The root bark is a Chinese herbal medicine called Moutan cortex, which has been used for a long time for the purpose of analgesia, blood purification, anti-inflammatory, etc. Also, peony (Paeonia lact)
iflora Pall) is widely cultivated to appreciate its flowers as flower plants. The roots of peony are used as crude drugs like buttons, and they are known to have effects such as analgesia, blood purification, and detoxification.

Scutella used in the present invention
ria L.) plants, in the Labiatae (Labiatae) plant, which is in northern China, herbs are widely distributed in Korea or semi-shrub, from East Siberia. Among the Scutellaria plants, in particular,
Scutellaria (Scutellaria baicalensis Georgi) and the roots of the same genus plants which are dry herbal scutellaria root (Scutel
lariae Radix ) is known to have anti-inflammatory, anti-microbial, antipyretic, hypotensive, diuretic and sedative effects.

As used in the present invention, the genus Astragalus (Me
Lissa L.) plant is a perennial belonging to Labiatae , and among them, Melissa officinalis L.
The extract of is often used.

Helianthus used in the present invention
L.) plant is a kind of dicotyledonous plant belonging to the family Asteraceae ( Compositae ), and among them, sunflower ( Helianthus annuus L.)
The extract of is often used. As a formulation of the sunflower extract to the external skin preparation, cosmetics containing the sunflower pressed oil meal extract (Japanese Patent Laid-Open No. 5-503522) and the like have already been disclosed. In the present invention, sunflower ( Helianthus annu
us, L.) can use flowers, seeds, stems, leaves and roots, but preferably flowers or seeds. Further, sunflower oil cake, which is a residue obtained by squeezing sunflower oil from seeds, may be used.

The Aloe L. plant used in the present invention is a woody succulent plant belonging to the family Liliaceae ,
Used as MotoHara plant of herbal "aloe" (Aloe).
As a plant belonging to the genus Aloe, Aloe ferox ( Aloe ferox Mill.), Which is a base plant of the herbal medicine "Aloe",
Aloe africana Mill. Aloe spicata Baker Aloe arborescens Mill. Aloe succotrina Lam. Aloe pricatilis Aloe
plicatilis Mill.), Aloe baines
ii Th. Dyer.), Aloe perryi Bake
r), aloe vera (in addition to the Aloe vera L.), etc., Kidachiaroe (A loe arborescens Mill.var. natalensis Ber
g.) can also be used. You may select and use 1 type (s) or 2 or more types from these.

The genus Polygonatu used in the present invention
m Adans.) plants, in one annual plant belonging to the Liliaceae (Liliac eae), herbal medicine "monarchy" (which is MotoHara plant of Polygonati Rhizoma) Narukoyuri (Polygonatum falcatum A. Gra
y), Polygonatum macranthum Koidzu
mi), and the related plant Kagyurumabanarukoyuri ( Po
lygonatum sibricum Red.), Carbanalco lily ( Pol
ygonatum stenophyllum Maxim.) and the like, and one or more of these may be selected and used.

The linseed (Linum L.) plant used in the present invention is an annual, biennial or perennial herb of the family Linaceae , and fiber, seed and seed oil are used. In particular,
Aminin oil obtained by squeezing alin (Lini Semen), which is a seed of flax ( Linum usitatissimum L.), under normal pressure is applied to paints, printing inks, varnishes, skin rubs, ointments and the like.

Rosa L. used in the present invention
The plant is a plant belonging to Rosaceae . Among them, Neubara ( Rosa multiflora Thunb.) Is a vine deciduous shrub of the Rosaceae family that grows naturally in Japan, and is a basic plant of the herbal medicine " Agees " ( Rosae Fructus ).
This closely related plant is the Teri Hanoi rose ( Rosa wichura
iana Crepin var. ampullicarpa Honda) and Fuji Ibaraki ( Rosa fujisanensis Makino).

The genus (Tilia L.) plant used in the present invention is a plant belonging to the family Tiliaceae,
The plants belonging to the genus Lindensis include American linden ( Tilia americana L.) and Fuyudaidai ( Tilia cord
ata Mill.), Tilia europaea
L.), linden (Tilia japonica Simonk.), Heranoki (Tilia kiusiana Makino et Shiras.) , Oba Odai Ju (Tilia maximowicziana Shiras.), Natsu linden (Tilia platyphyllos Scop.), Linden (Tilia
miqueliana Maxim.) and the like.

[0016] The genus Hepatica used in the present invention
rotropa Morr. et Decne) is a plant belonging to the family Aristolochiaceae, and recent studies have shown that the genus Drosophila (Asarum L.), the genus Hexastylis L., and the genus Asiasarum (Asiasarum).
L.) etc. are also included. Among them, saishin is a base plant of crude drug "Saishin" (Asiasari Radix), and from the viewpoint of effectiveness, russia ( Asiasarum siebol)
dii F. Maekawa) or Keirin Saishin ( Asiasarum
heterotropoides var. mandshuricum F. Maekawa), a closely related plant, clofunacicin (Asiasarum dimidi)
atum F. Maekawa), quezozoicin ( Asiasarum het
erotropoides F. Maekawa), Usugesaishin ( Asiasaru
m heterotropoides var. seoulense F. Maekawa), Ishinami Nana (Asarum himalaicum Hook.f.et Thoms.ex Klotzc
h) and the like.

Houttuyn used in the present invention
The ia Thunb.) plant is a plant that belongs to the family Lentilaceae (Saururaceae). Above all, Houttuynia cordata
Thunb.) Is a member of the Saururaceae family and is distributed throughout Asia except in the north. In Japan, there are odorous perennial herbs that grow naturally in the wetlands of various places, and the stems are high.
It will be 20-50 cm. In the early summer, the spikes are borne on top, and the inflorescences are surrounded by white petal-shaped envelopes, so they look like a single flower.
In Japan, ten herbs, "juyaku" (Houttuyniae Herb)
a) or also known as the heavy medicine "juuyaku", diuresis, fever,
It is used for the treatment of swelling, hypertension, pulmonary gangrene (eso), pulmonary tuberculosis, common cold, empyema, hemorrhoids, constipation, etc. because it has the effect of purulent drainage and detoxification.

The genus Canto (Tussilago) used in the present invention
L.) plants belong to the family Asteraceae ( Compositae ). Among them, coltsfoot ( Tussilago farfara L.)
Is a perennial herb whose young leaves are edible and widely medicated. It is often used for respiratory diseases, and inhalation of smoke is said to be effective for asthma. In Chinese medicine, it is used for antitussive, expectorant, and asthma.

The genus Sanguisorb used in the present invention
a L.) plant is a plant belonging to Rosaceae . Among them, the warremoko ( Sanguisorba officinalis
L.) is a perennial herb that grows wild in our country around, used as MotoHara plant of herbal "healing" (S anguisorba Radix).

Mentha used in the present invention
L.) plant is a plant of the Lamiaceae family, and is known as spearmint, Mentha spicata Linne.
And, peppermint (Mentha piperita L.) and its variants or, peppermint (Menthaarvensis L. var. Piper
ascens Malin.) etc. It is used as a mouthwash, stomach medicine, analgesic, fatigue recovery agent, preservative, etc.

Sambucus used in the present invention
L.) plants are plants belonging to the family Lonicerae ( Caprifoliaceae ). As a typical example, the elderberry ( S
ambucus nigra L.), which is known for tall trees that grow from a shrub to a height of about 10 m. It is distributed from Europe to North Africa and is cultivated in gardens and botanical gardens. Black-purple fruits are edible, and in Europe they are fermented to produce wine and used for coloring wine, and flowers are used as sweating and stimulants.

[Plant Extract] Next, an extraction method for obtaining a plant extract of the above components will be described. The above plants are various kinds of whole plants or leaves, stems, stems, branches, branches and leaves, pericarps,
One or more places such as fruits, bark, sap, seeds, rhizomes, root bark, roots, spikes, head flowers, flowers, etc. are used as they are or after being dried. The extraction solvent is not particularly limited,
1 such as water, ethanol, methanol, isopropanol, isobutanol, n-hexanol, methylamyl alcohol, 2-ethylbutanol, n-octyl alcohol
Polyhydric alcohols such as polyhydric alcohols, glycerin, ethylene glycol, ethylene glycol monomethyl ether, propylene glycol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, triethylene glycol, 1,3-butylene glycol and hexylene glycol, or derivatives thereof. ,acetone,
Methyl ethyl ketone, methyl isobutyl ketone, methyl
-Ketones such as n-propyl ketone, esters such as ethyl acetate and isopropyl acetate, ethers such as ethyl ether, isopropyl ether and n-butyl ether, hydrocarbons such as squalane, petrolatum, paraffin wax and paraffin oil, olive oil , Vegetable oils and fats such as wheat germ oil, rice oil, sesame oil, macadamian nut oil, almond oil and coconut oil, and animal oils and fats such as beef tallow, lard and whale oil. Further, a polar solvent added with an inorganic salt such as phosphate buffered saline or a solvent added with a surfactant can be used, and there is no particular limitation. Among these extraction solvents, when polar solvents such as ethanol, 1,3-butylene glycol and aqueous solutions thereof are used, particularly effective AGEs are obtained.
A production suppressing effect is recognized.

Further, the extraction method includes a method of impregnation at room temperature, a state of being cooled or heated, an extraction method using a distillation method such as steam distillation, and a pressing method of pressing a plant to obtain an extract. For example, these methods can be used alone or in combination of two or more to perform extraction.

The ratio of the plant to the solvent at the time of extraction is not particularly limited, but 0.1 to 1000 times by weight of the solvent relative to the plant 1, particularly 0.5 to 100 times by weight in terms of extraction operation and efficiency. preferable. The extraction pressure and temperature are 0 ℃ under normal pressure.
To the boiling point of the solvent or less is convenient, and the extraction time is preferably 2 hours to 2 weeks, although it depends on the extraction temperature and the like.

As the AGEs production inhibitor containing the plant extract thus obtained as an active ingredient, the extract can be used as it is, but as long as the effect is not lost, deodorization, decolorization, concentration, etc. It may be used as a fractionated product by applying the purification operation described above or further using column chromatography or the like. These extracts, purified products, and fractionated products can be made into a dried product by removing the solvent from them, and can be used in the form of being solubilized in a solvent such as alcohol, or in the form of an emulsion. it can.

The external preparation for skin according to the present invention uses one or more selected from the above components as an AGEs production inhibitor. The amount of these components to be added to the external preparation for skin is 0.0, considering the effect, odor when added, and color tone.
The concentration range is preferably 0001 to 20% by weight, and more preferably 0.0001 to 5% by weight.

The external preparation for skin according to the present invention may be in any form such as cream, ointment, lotion, emulsion, solid form, powder, and basic makeup such as lotion, emulsion, beauty essence and moisturizing cream. Suncare products such as sunscreen, sunscreen cream, sunscreen lotion, suntan oil, carmine lotion, foundation, eyeliner,
Makeup cosmetics such as mascara, eye color, cheek color, lipstick, etc., facial cleanser, body shampoo, hair shampoo, etc., rinse, treatment, hair cream, hair oil, hair dressing etc., hair cosmetics, perfume, deodorant It can be provided in the form of an antiperspirant or the like.

At that time, within a range that does not impair the effects of the present invention, an oily component, a surfactant, a moisturizer, a pigment, an ultraviolet absorber, an antioxidant, a fragrance, which are generally used for external preparations for skin,
It is possible to include general raw materials for medicines and cosmetics such as antibacterial and antifungal agents, and physiologically active ingredients such as skin cell activating agents and anti-inflammatory agents.

[0029]

EXAMPLES Next, the present invention will be described in more detail with reference to Examples, but it goes without saying that the present invention is not limited to these Examples. The percentages used below are weight percentages unless otherwise specified.

<Example 1> AGEs formation inhibitor 1 300 g of root bark of button (Paeonia suffruticosa Andr.)
Is dried and crushed, and a 50% by volume ethanol aqueous solution 3,000
It was extracted with stirring in 0 ml at 25 ° C. for 7 days. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 1.

<Example 2> AGEs production inhibitor 2 215 g of Scutellariae Radix was added at 50% by volume.
The mixture was extracted with stirring in 2500 ml of an aqueous ethanol solution at 25 ° C. for 7 days. The extract is filtered, and the filtrate is recovered to AGE
s production inhibitor 2.

<Example 3> AGEs formation inhibitor 3 200 g of leaves of Melissa officinalis L.
25 ° C in 2,000 ml of 0% by volume ethanol aqueous solution
It was extracted with stirring for 7 days. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 3.

<Example 4> AGEs production inhibitor 4 50 g of sunflower ( Helianthus annuus L.) seeds 300 g
Extraction was performed by stirring in 3000 ml of a volume% aqueous ethanol solution at 25 ° C. for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 4.

<Example 5> AGEs formation inhibitor 5 Aloe arborescens Mill. Var. Natalens
is Berg.) leaves (500 g) were extracted by stirring in 5,000 ml of 50% by volume aqueous ethanol at 25 ° C. for 7 days with stirring. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 5.

<Example 6> AGEs production inhibitor 6 Rhizome 1 of narcoli ( Polygonatum falcatum A. Gray)
00 g was extracted by stirring in 1,000 ml of 50% by volume aqueous ethanol at 25 ° C. for 7 days with stirring. The extract was filtered and the filtrate was collected as AGEs production inhibitor 6.

<Example 7> AGEs production inhibitor 7 100 g of amanine (Lini Semen) was extracted with stirring in 1,000 ml of 50% by volume aqueous ethanol at 25 ° C for 7 days. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 7.

<Example 8> AGEs production inhibitor 8 150 g of fruits of Noibara ( Rosa multiflora Thunb.) Were added to 25 ml of 1,500 ml of 50% by volume aqueous ethanol solution.
The mixture was extracted with stirring at 7 ° C for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 8.

<Example 9> AGEs production inhibitor 9 250 g leaves of bodaiju ( Tilia miqueliana Maxim.)
2 in 50 ml of 50% by volume aqueous ethanol solution.
The mixture was extracted with stirring at 5 ° C for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 9.

<Example 10> AGEs production inhibitor 10 350 g of roots and rhizomes of Usabasaicin ( Asiasarum sieboldii F. Maekawa) were mixed with a 50% by volume aqueous ethanol solution.
It was extracted by stirring in 500 ml at 25 ° C. for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 10.

<Example 11> AGEs production inhibitor 11 Whole plant 300 of Houttuynia cordata Thunb.
g was extracted with stirring in 3,000 ml of 50% by volume aqueous ethanol at 25 ° C. for 7 days with stirring. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 11.

<Example 12> AGEs production inhibitor 12 Flower and leaf of coltsfoot ( Tussilago farfara L.) 20
0 g was extracted with stirring in 2,000 ml of 50% by volume aqueous ethanol at 25 ° C. for 7 days with stirring. The extract was filtered, and the filtrate was collected as the AGEs production inhibitor 12.

<Example 13> AGEs formation inhibitor 13 150 g of roots and rhizomes of Waremoko ( Sanguisorba officinalis L.) were mixed with 1,500 m of 50% by volume aqueous ethanol solution.
It was extracted by stirring in 1 l at 25 ° C. for 7 days. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 13.

<Example 14> AGEs production inhibitor 14 Above ground part 250 of Mentha spicata Linne
g was extracted with stirring in 2,500 ml of 50% by volume aqueous ethanol at 25 ° C. for 7 days with stirring. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 14.

<Example 15> AGEs formation inhibitor 15 450 g of leaves of Sambucus nigra L. were prepared in 25% in 4,500 ml of 50% by volume aqueous ethanol solution.
The mixture was extracted with stirring at 7 ° C for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 15.

<Example 16> AGEs production inhibitor 16 Roots of button (Paeonia suffruticosa Andr.) 300 g
Was dried, pulverized, and extracted by stirring in 3,000 ml of 50% by volume 1,3-butylene glycol aqueous solution at 25 ° C. for 7 days with stirring. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 16.

<Example 17> AGEs production inhibitor 17 215 g of Scutellariae Radix was added at 50% by volume.
The mixture was extracted with stirring in 2,500 ml of 1,3-butylene glycol aqueous solution at 25 ° C. for 7 days with stirring. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 17.

<Example 18> AGEs production inhibitor 18 5 g of 200 g of leaves of Melissa officinalis L.
0% by volume 1,3-butylene glycol aqueous solution 2,000
It was extracted by stirring in ml at 25 ° C. for 7 days. The extract was filtered, and the filtrate was collected as the AGEs production inhibitor 18.

<Example 19> AGEs production inhibitor 19 300 g of sunflower ( Helianthus annuus L.) seeds (50 g) were added .
Volume% 1,3-butylene glycol aqueous solution 3,000 m
It was extracted by stirring in 1 l at 25 ° C. for 7 days. The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 19.

<Example 20> AGEs production inhibitor 20 Aloe arborescens Mill. Var. Natalens
is Berg.) leaves (500 g) were extracted by stirring in 5,000 ml of 50% by volume 1,3-butylene glycol aqueous solution at 25 ° C. for 7 days with stirring. The extract is filtered, and the filtrate is recovered to AGE
s production inhibitor 20.

<Example 21> AGEs production inhibitor 21 Root of rhubarb ( Polygonatum falcatum A. Gray) 1
00 g was extracted by stirring in 1,000 ml of 50% by volume 1,3-butylene glycol aqueous solution at 25 ° C. for 7 days with stirring. The extract is filtered, and the filtrate is collected to suppress the AGEs production 21
And

<Example 22> AGEs production inhibitor 22 100 g of amanine (Lini Semen) was added at 50% by volume of 1,3-
25 ℃ in 1,000 ml of butylene glycol aqueous solution
It was extracted with stirring for 7 days. The extract was filtered, and the filtrate was collected as the AGEs production inhibitor 22.

<Example 23> AGEs formation inhibitor 23 150 g of fruit of Noibara ( Rosa multiflora Thunb.) Was added to 50% by volume of 1,3-butylene glycol aqueous solution 1,50.
It was extracted with stirring in 0 ml at 25 ° C. for 7 days. The extract was filtered, and the filtrate was collected as the AGEs production inhibitor 23.

<Example 24> AGEs formation inhibitor 24 250 g of flower of Tilia miqueliana Maxim.
50% by volume of 1,3-butylene glycol aqueous solution 2.5
The mixture was extracted with stirring in 00 ml at 25 ° C. for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 24.

Example 25 Inhibitor 25 of AGEs Production 350 g of roots and rhizomes of Usabasaicin ( Asiasarum sieboldii F. Maekawa) were stirred in 3,500 ml of 50% by volume 1,3-butylene glycol aqueous solution at 25 ° C. for 7 days. Extracted. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 25.

<Example 26> AGEs production inhibitor 26 Whole plant 300 of Houttuynia cordata Thunb.
g of 50% by volume 1,3-butylene glycol aqueous solution 3,
The mixture was extracted with stirring in 000 ml at 25 ° C for 7 days. The extract was filtered, and the filtrate was collected as AGEs production inhibitor 26.

<Example 27> AGEs production inhibitor 27 Flower and leaf of coltsfoot ( Tussilago farfara L.) 20
0 g was extracted by stirring in 2,000 ml of 50% by volume 1,3-butylene glycol aqueous solution at 25 ° C. with stirring for 7 days. The extract is filtered, and the filtrate is collected to suppress the AGEs production 27
And

<Example 28> AGEs production inhibitor 28 150 g of roots and rhizomes of Japanese cabbage ( Sanguisorba officinalis L.) were extracted by stirring in 1,500 ml of 50% by volume 1,3-butylene glycol aqueous solution at 25 ° C. for 7 days. . The extract was filtered, and the filtrate was recovered as AGEs production inhibitor 28.

<Example 29> AGEs production inhibitor 29 250 g of leaves of Mentha spicata Linne were mixed with 50% by volume of 1,3-butylene glycol aqueous solution 2,50
It was extracted with stirring in 0 ml at 25 ° C. for 7 days. The extract was filtered and the filtrate was used as AGEs production inhibitor 29.

<Example 30> AGEs production inhibitor 30 450 g of a flower of Sambucus nigra L. was mixed with 50% by volume of a 1,3-butylene glycol aqueous solution of 4,50.
It was extracted with stirring in 0 ml at 25 ° C. for 7 days. The extract was filtered, and the filtrate was collected as the AGEs production inhibitor 30.

Next, Examples 1, 2, 3, 5, 7, 8, 9, 10, 1
Regarding the AGEs production inhibitors shown in 1, 12, 13, and 15,
The AGEs production inhibitory effect was investigated.

The test was carried out using 1 m of bovine fetal serum albumin (Bovine Serum Albumin) as protein.
g / ml, using glucose 50 mM as a reducing sugar, reacting in a sample tube at 50 ° C. for 5 days in a shaking incubator, adding an appropriate amount of an AGEs production inhibitor,
AGEs compared to those without the addition of a production inhibitor
It was evaluated based on whether or not the generation of was suppressed. AGEs
The amount produced is 405 by the ELISA method using the AGEs antibody.
by measuring the absorbance at nm or 360-49
It quantified by the fluorescence intensity measuring method which measures the fluorescence intensity of 0 nm. At that time, using standard AGEs, a calibration curve was prepared and quantified.

The AGEs production suppression rate (%) is calculated by the following equation. AGEs production inhibitor rate (%) = (Sample value containing AGEs production inhibitor) / (Sample value without AGEs production inhibitor) × 100

Table 1 shows the AGEs production inhibition rate of the AGEs production inhibitor of the present invention by the ELISA method. From these results, it can be seen that the AGEs production inhibitor of the present invention exerts an AGEs production inhibitory action.

[0064]

[Table 1]

Next, the AG of the present invention is measured by a fluorescence intensity measuring method.
Table 2 shows the AGEs production inhibitory effect of the Es production inhibitor.
From this result, the AGEs production inhibitor of the present invention is
It can be seen that it exerts a production suppressing action.

[0066]

[Table 2]

Next, a lotion according to Example 31 was prepared according to the formulation shown in Table 3. In addition, this lotion is (2) ~
An alcohol phase in which (5) was dissolved was prepared by uniformly mixing (6) to (11), adding to the dissolved aqueous phase, and then uniformly mixing.

[0068]

[Table 3]

In Example 31 of the present invention, a practical use test for 6 months was conducted. A formulation containing no AGEs production inhibitor was used as a comparative example. In the practical use test, as a panel, 20 females in their 40s to 60s who exhibited remarkable skin aging symptoms such as wrinkles and decreased skin elasticity were used as 20 groups per group, and each Example and Comparative Example were blinded. I used it twice a day. The skin condition was observed before and after the start of the use test, and the improvement status of wrinkles and skin elasticity was evaluated in three stages of "improved", "slightly improved" and "no change". The degree of wrinkles was evaluated by photographing and replica sampling, and the elasticity of the skin was evaluated by measuring with a cute meter. The results are shown in Table 4 by the number of panelists who obtained each evaluation.

[0070]

[Table 4]

As is clear from Table 4, in Example 31 of the present invention, both panel wrinkles and skin elasticity showed a tendency toward improvement in symptoms. On the other hand, in the comparative example in which the AGEs production inhibitor was not blended, there were no panelists in which wrinkles and skin elasticity were clearly improved.

Next, in Example 31 of the present invention, 20 female panelists having pigmentation symptoms such as yellowish tinge were subjected to an actual use test for 6 months to evaluate the effect of improving pigmentation symptoms. . A formulation containing no AGEs production inhibitor was used as a comparative example. Each group was used in Example 31 and the comparative example twice a day for 2 weeks in a blind, and after 2 weeks, the state of skin pigmentation was observed and evaluated in comparison with that before use. The state of pigmentation was evaluated according to the criteria shown in Table 5 based on images taken before and after use, and the average value of 20 persons was calculated and shown in Table 7.

[0073]

[Table 5]

[0074]

[Table 6]

As is clear from Table 6, in Example 31 of the present invention, a remarkable improvement in the pigmentation symptom was observed, and the tendency of the symptom improvement was observed in all the panelists. After the end of the use test, the symptoms were improved to the extent that mild or slight pigmentation was observed. On the other hand, in the formulation containing no AGEs production inhibitor, which is a comparative example, no improvement in pigmentation symptoms was observed.

Next, another embodiment of the present invention will be shown.

<Example 32> Oil-in-water emulsion type cream (1) Squalane 10.00 (% by weight) (2) Octyldodecyl myristate 5.00 (3) Hydrogenated soybean phospholipid 0.20 (4) Batyl alcohol 3.00 (5) Hardened oil 2.00 (6) Stearic acid 1.50 (7) Lipophilic glyceryl monostearate 1.50 (8) Polyglyceryl monostearate 1.50 (9) Behenyl alcohol 0.80 ( 10) Polyglyceryl monomyristate 0.70 (11) White beeswax 0.30 (12) Mixed fatty acid triglyceride 0.10 (13) d-δ-tocopherol 0.05 (14) Stearyl glycyrrhetinate 0.05 (15) Purified Water remaining (16) Xanthan gum 0.20 (17) Purified water 19.80 (18) 1,3-Butylene glycol 15.00 (19) Paraoxybenzoic acid ester 0.10 (20) Sodium hydroxide .20 (21) Purified water 1.80 (22) AGEs production inhibitor 7 0.10 (23) AGEs production inhibitor 4 0.10 (24) AGEs production inhibitor 1 0.50 (25) AGEs production inhibitor 2 0.50 (26) AGEs production inhibitor 3 0.50 (27) AGEs production inhibitor 20 0.10 (28) AGEs production inhibitor 24 0.10 (29) AGEs production inhibitor 21 0.10 (30 ) Fragrance 0.15 (31) Ethanol 2.00 Production method: After heating the oil phase components (1) to (14) and the water phase components (15) to (19) to 80 ° C. and mixing and homogenizing , Add the oil phase to the water phase. Furthermore, it was mixed and dissolved in advance (20) ~
Add (21) and emulsify with a homomixer. Cool with stirring, premix at 40 ° C and dissolve (22)-(29) and (3
Add components (0) to (31), stir and homogenize.

<Example 33> Beauty essence (1) Polyglyceryl distearate 2.50 (% by weight) (2) Glyceryl tri-2-ethylhexanoate 8.00 (3) Hydrogenated soybean phospholipid 0.50 (4) ) Lipophilic glyceryl monostearate 0.50 (5) Behenyl alcohol 0.50 (6) Glycerin 7.50 (7) Purified water balance (8) Xanthan gum 0.40 (9) Ethanol 8.00 (10) AGEs Production inhibitor 8 0.10 (11) AGEs production inhibitor 9 0.10 (12) AGEs production inhibitor 10 0.10 (13) AGEs production inhibitor 26 0.10 (14) AGEs production inhibitor 27 0. 10 (15) AGEs production inhibitor 28 0.10 (16) AGEs production inhibitor 25 0.10 Production method: 70 parts of the components (1) to (5) and (6) to (8), respectively.
After heating to ℃ to mix and dissolve, both components are mixed and emulsified with a homomixer. The mixture is cooled with stirring, and the components (9) to (16) previously mixed and dissolved at 40 ° C. are added, mixed and homogenized.

<Example 34> Lotion (1) Purified water Remaining amount (% by weight) (2) Ethanol 8.00 (3) Paraoxybenzoic acid ester 0.05 (4) Carboxyvinyl polymer 0.05 (5) Purified water 4.95 (6) Xanthan gum 0.10 (7) Purified water 9.90 (8) 1,3-butylene glycol 3.00 (9) Concentrated glycerin 15.00 (10) L-arginine 0.10 ( 11) Purified water 0.90 (12) AGEs production inhibitor 6 0.10 (13) AGEs production inhibitor 14 0.10 (14) AGEs production inhibitor 15 0.10 (15) AGEs production inhibitor 16 0. 20 (16) AGEs production inhibitor 17 0.20 (17) AGEs production inhibitor 18 0.20 (18) AGEs production inhibitor 30 0.20 Manufacturing method: Ingredients (2) to (18) are added to (1). Add sequentially, mix,
Dissolve and homogenize.

Example 35 Cleansing Cream (1) Stearic Acid 2.00 (wt%) (2) Cetanol 3.00 (3) Vaseline 10.00 (4) Squalane 38.00 (5) Isopropyl myristate 10 0.000 (6) Tocopherol acetate 0.10 (7) Glyceryl monostearate 2.50 (8) Polyoxyethylene (20 E.O.) sorbitan monostearate 2.50 (9) Propylene glycol 5.00 ( 10) Methyl paraoxybenzoate 0.10 (11) Purified water Residual amount (12) Potassium hydroxide 0.20 (13) Purified water 1.80 (14) AGEs production inhibitor 19 0.15 (15) AGEs production inhibition Agent 22 0.15 (16) AGEs production inhibitor 23 0.15 (17) AGEs production inhibitor 29 0.15 (18) AGEs production inhibitor 13 0.15 (19) AGEs production inhibitor 11 0.15 ( 2 0) AGEs production inhibitor 12 0.15 (21) AGEs production inhibitor 5 0.15 (22) Perfume 0.10 Production method: The oil phase components of (1) to (8) are mixed and heated to 70 ° C.
And On the other hand, the water phase components (9) to (11) are mixed and dissolved to form 7
Heat to 0 ° C. After gradually adding the oil phase to this aqueous phase component, (12) to (13) are added and uniformly emulsified with a homomixer. After emulsification, after cooling to 40 ℃, (14) ~ (21),
(22) is sequentially added and mixed.

With respect to Examples 32 to 35 of the present invention, the effects of improving wrinkles, skin elasticity and pigmentation symptoms were evaluated, and the improving effects were confirmed in all Examples.

When Examples 1 to 35 of the present invention were stored at 10 ° C. or lower, the effect of suppressing the generation of AGEs was maintained substantially unchanged for 6 months. Furthermore, even when Examples 1 to 35 of the present invention were stored at 25 ° C. for 6 months, no change was observed in the AGEs production inhibitory effect and the formulation state. Furthermore, in the above actual use test,
In the use group of the examples of the present invention, no panelists recognized skin irritation reaction or skin sensitization reaction, and a panelist who complained of irritation or discomfort such as pain and warmth, tingling sensation, tingling sensation during use. Did not exist either.

[0083]

As described in detail above, according to the present invention, an excellent AGEs production inhibitor, and an agent containing the same as an active ingredient, which has an effect of preventing and improving aged skin and aging skin, and is compatible with the skin. It was possible to obtain an external preparation for skin which has good stability and is excellent in formulation stability and safety.

─────────────────────────────────────────────────── ───

[Procedure amendment]

[Submission date] October 21, 2002 (2002.10.
21)

[Procedure Amendment 1]

[Document name to be amended] Statement

[Name of item to be corrected] Claim 1

[Correction method] Change

[Correction content]

[Procedure Amendment 2]

[Document name to be amended] Statement

[Name of item to be corrected] 0005

[Correction method] Change

[Correction content]

[0005]

Upon solving the above problems BRIEF SUMMARY OF THE INVENTION, it was subjected to various studies, peony extract
Stuff, euphorbiaceae plant extract, sunflower plant
Extract, flaxseed plant extract, flax plant extract,
Rose genus extract, linden genus plant extract, algal bloom
Genus plant extract, Dokudami plant extract, Kanto plant
One or more components of an extract, an extract of the genus Vaccinium, an extract of the genus Mint suppress the production of AGEs, or a skin external preparation containing the same as an AGEs production inhibitor It was found that an external preparation for skin that exhibits a yellow gustiness and protection against aging skin, exhibits an improving effect, and has no safety problems such as skin irritation and skin sensitization, and completed the present invention.

[Procedure 3]

[Document name to be amended] Statement

[Correction target item name] 0008

[Correction method] Delete

[Procedure amendment 4]

[Document name to be amended] Statement

[Correction target item name] 0011

[Correction method] Delete

[Procedure Amendment 5]

[Document name to be amended] Statement

[Correction target item name] 0021

[Correction method] Delete

Continued front page    F-term (reference) 4C083 AA082 AA111 AA112 AA122                       AB032 AC012 AC022 AC072                       AC102 AC122 AC242 AC352                       AC422 AC442 AC482 AC582                       AD042 AD092 AD352 AD532                       AD572 AD662 CC04 CC05                       CC23 DD31 DD33 EE05 EE12                       EE16

Claims (2)

[Claims] 1. A button genus plant extract, a skullcap genus plant extract, a genus Astragalus genus plant extract, a sunflower genus plant extract, an aloe genus plant extract, an amadochorus plant extract, an flax genus plant extract, a rose genus 1 or 2 of a plant extract, a linden plant extract, a citrus plant extract, a Dodami plant extract, a citrus plant extract, an oleracea plant extract, a mint plant extract, an elderberry plant extract Advanced glycation end products production inhibitor consisting of more than one ingredient. 2. One or two of the plant extracts according to claim 1.
An external preparation for the skin, which comprises one or more seeds as an advanced glycation end products formation inhibitor.